


# AGA releases official guidance for patients with IBD during the COVID-19 pandemic

April 11 2020

## Management of Patients with IBD during the COVID-19 Pandemic

Source: Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology (2020)



Management of Patients with IBD during the COVID-19 Pandemic Credit: American Gastroenterology Association

Today, the American Gastroenterological Association (AGA) published new COVID-19 guidance for gastroenterologists treating patients with inflammatory bowel disease (IBD): [AGA Clinical Practice Update on](#)

## Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.

While the COVID-19 pandemic is a global health emergency, patients with IBD have particular concerns for their risk for infection and management of their medical therapies. This clinical practice update incorporates the emerging understanding of COVID-19 and summarizes available guidance for patients with IBD and the providers who take care of them.


Recommendations for gastroenterologists & their patients who have IBD:

1. During this pandemic, patients with IBD should continue IBD therapies including scheduled infusions.
2. Having IBD does not appear to increase the risk of SARS-CoV-2 infection or the development of COVID-19.
3. Instructions for [patients](#) with IBD who develop COVID-19 (fever, respiratory symptoms, digestive symptoms, etc.):
  - a. Stop thiopurines, methotrexate, tofacitinib.
  - b. Stop biological therapies (including anti-TNF, ustekinumab, vedolizumab).
  - c. Can restart therapies after complete resolution of COVID-19 symptoms. Patients should  
  
always speak with their health care team before stopping any medication.


4. Doctors should submit cases of IBD and confirmed COVID-19 to the SECURE-IBD registry at COVIDIBD.org.

AGA Clinical Practice Update


## Management of Inflammatory Bowel Disease During the COVID-19 Pandemic



Patients with IBD should continue IBD therapies and infusions.




Having IBD doesn't appear to increase the risk of SARS-CoV-2 infection or development of COVID-19.




Instructions for IBD patients who develop COVID-19 (fever, respiratory symptoms, digestive symptoms):


- Stop thiopurines, methotrexate, tofacitinib.
- Stop biological therapies (including anti-TNF, ustekinumab, vedolizumab).
- Can restart therapies after complete resolution of COVID-19 symptoms.



Patients with IBD - speak with your health care team before stopping any medication



Submit cases of IBD and confirmed COVID-19 to the SECURE-IBD registry at [COVIDIBD.org](https://COVIDIBD.org).

 American Gastroenterological Association

Source: Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. *Gastroenterology* (2020)

Management of IBD During the COVID-19 Pandemic. Credit: American Gastroenterology Association

**More information:** David T. Rubin et al, AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary, *Gastroenterology* (2020). DOI: [10.1053/j.gastro.2020.04.012](https://doi.org/10.1053/j.gastro.2020.04.012)

Provided by American Gastroenterological Association

Citation: AGA releases official guidance for patients with IBD during the COVID-19 pandemic (2020, April 11) retrieved 4 May 2024 from <https://medicalxpress.com/news/2020-04-aga-guidance-patients-ibd-covid-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.